GSK (NYSE:GSK) Upgraded at StockNews.com

GSK (NYSE:GSK) was upgraded by equities researchers at StockNews.com from a “buy” rating to a “strong-buy” rating in a report issued on Thursday.

Several other analysts have also commented on GSK. Morgan Stanley assumed coverage on shares of GSK in a research report on Wednesday, February 12th. They issued an “equal weight” rating on the stock. BNP Paribas assumed coverage on GSK in a report on Tuesday, April 15th. They set a “neutral” rating and a $35.25 target price on the stock. Eight investment analysts have rated the stock with a hold rating and four have issued a strong buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $40.58.

GSK Stock Performance

Shares of GSK stock opened at $37.03 on Thursday. The stock has a fifty day moving average price of $37.46 and a 200 day moving average price of $36.06. The company has a debt-to-equity ratio of 1.12, a quick ratio of 0.52 and a current ratio of 0.78. The stock has a market cap of $76.41 billion, a PE ratio of 23.29, a P/E/G ratio of 1.12 and a beta of 0.56. GSK has a 1 year low of $31.72 and a 1 year high of $45.93.

GSK (NYSE:GSK) last released its quarterly earnings results on Wednesday, February 5th. The pharmaceutical company reported $0.59 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.44 by $0.15. GSK had a return on equity of 48.59% and a net margin of 8.13%. Sell-side analysts forecast that GSK will post 4.14 earnings per share for the current fiscal year.

Hedge Funds Weigh In On GSK

Several institutional investors have recently added to or reduced their stakes in GSK. FMR LLC lifted its holdings in shares of GSK by 82.1% during the 4th quarter. FMR LLC now owns 52,823,032 shares of the pharmaceutical company’s stock worth $1,786,475,000 after acquiring an additional 23,814,104 shares during the period. Primecap Management Co. CA raised its stake in GSK by 70.1% during the fourth quarter. Primecap Management Co. CA now owns 25,261,660 shares of the pharmaceutical company’s stock worth $854,349,000 after purchasing an additional 10,407,905 shares during the period. Voloridge Investment Management LLC boosted its holdings in shares of GSK by 1,360.4% in the 4th quarter. Voloridge Investment Management LLC now owns 2,165,043 shares of the pharmaceutical company’s stock valued at $73,222,000 after purchasing an additional 2,016,795 shares during the last quarter. Bridgewater Associates LP boosted its holdings in shares of GSK by 132.7% in the 4th quarter. Bridgewater Associates LP now owns 2,247,691 shares of the pharmaceutical company’s stock valued at $76,017,000 after purchasing an additional 1,281,855 shares during the last quarter. Finally, Woodline Partners LP purchased a new stake in shares of GSK during the 4th quarter valued at $36,665,000. 15.74% of the stock is currently owned by institutional investors and hedge funds.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.